Amarantus Bioscience Holdings Inc (AMBS)

[betelgeuse]

Eli Lilly is continuing to pursue its stage-three trial of solanezumab since the data indicate that it slowed cognitive decline in early-stage patients by 34 percent. All pharmaceuticals in Alzheimer's research are unanimous that the key to cure Alzheimer's could lie in the early detection of the symptoms. LymPro, a blood based diagnostic assay being developed by Amarantus BioScience Holdings Inc. (ticker AMBS) has shown 98%/96% sensitivity/specificity in detecting and distinguishing Alzheimer's from other forms of dementia, in a study of 160 patient population. LymPro is currently undergoing validation tests at the Becton Dickinson (BD) diagnostic systems. A successful trail could kick-start efforts to cure Alzheimer's in what is potentially a 20 billion dollar market.


AMBS will be releasing data related to its various milestones in the second week of September. Being a scientist, one thing I can tell you what researchers and scientists absolutely love and drool on: POSITIVE DATA. How many of you seriously think that with billions of dollars to tap, no pharmaceutical company is looking at or interested in LymPro? Just wait until AMBS officially releases the BD results (which I can confirm are outrageously good). You will get your answers.

Be proactive, is all I can say.